SOST and cardiovascular disorder: In this review, we summarized pre-marketing and post-marketing cardiovascular safety evaluations of romosozumab, discussed the association between SOST variants and cardiovascular diseases, and integrated the data analyzing the association between sclerostin and the presence/severity/outcomes of cardiovascular diseases.